NasdaqGM:XENEBiotechs
Xenon Pharmaceuticals (XENE) Could Be 14% Undervalued If Its Epilepsy Narrative Holds
Xenon Pharmaceuticals (XENE) has attracted attention after recent share price moves, with the stock closing at $68.92. Investors are weighing its performance over the past month and past 3 months, alongside longer term returns.
See our latest analysis for Xenon Pharmaceuticals.
The recent 1 day share price decline of 2.87% comes after a strong run, with a 30 day share price return of 32.28% and a year to date share price return of 54.91%. The 1 year total shareholder return of 111.41% points...